Validation by calibration of the UCLA integrated staging system prognostic model for nonmetastatic renal cell carcinoma after nephrectomy

Cancer

Volumn 113, Issue 1, 2008, Pages 65-71

  Cindolo, Luca ^a   Chiodini, Paolo ^b   Gallo, Ciro ^b   Ficarra, Vincenzo ^c   Schips, Luigi ^d   Tostain, Jacques ^e   De La Taille, Alexandre ^f   Artibani, Walter ^c   Patard, Jean Jacques ^g  

^a G RUMMO HOSPITAL   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d UNIVERSITY HOSPITAL GRAZ   (Austria)

^e UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^f HENRI MONDOR HOSPITAL   (France)

^g UNIVERSITÉ DE RENNES 1   (France)

Author keywords

Integrated Staging System (UISS); Prognosis; Renal cancer; Score; University of California at Los Angeles (UCLA); Validation by calibration

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CALIBRATION; CANCER STAGING; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; EUROPE; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; UNITED STATES; VALIDATION PROCESS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CALIBRATION; CARCINOMA, RENAL CELL; CHILD; FEMALE; HUMANS; KIDNEY NEOPLASMS; LOS ANGELES; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASM STAGING; NEPHRECTOMY; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 47149086246     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23517     Document Type: Article

References (27)

1. Ljungberg B, Hanbury DC, Kuczyk MA, et al. Renal cell carcinoma guidelines. Eur Urol. 2007;51:1502-1510.
2. Lau WK, Blute ML, Weaver AL, et al. Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney. Mayo Clin Proc. 2000;75:1236-1242.
3. Eisen T. Adjuvant therapy in renal cell carcinoma: where are we? Eur Urol Suppl. 2007;6:492-498.
4. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125-134.
5. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-124.
6. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271-2281.
7. Johannsen M, Brinkmann OA, Bergmann L, et al. The role of cytokine therapy in metastatic renal cell cancer. Eur Urol Suppl. 2007;6:658-664.
8. Lam JS, Leppert JT, Belldegrun AS, Figlin RA. Adjuvant therapy of renal cell carcinoma: patient selection and therapeutic options. BJU Int. 2005;96:483-488.
9. Kattan MW, Reuter V, Motzer RJ, et al. A postoperative prognostic nomogram for renal cell carcinoma. J Urol. 2001;166:63-67.
10. Zisman A, Pantuck AJ, Wieder J, et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol. 2002;20:4559-4566.
11. Frank I, Blute ML, Cheville JC, et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol. 2002;168:2395-2400.
12. Yaycioglu O, Roberts WW, Chan T, et al. Prognostic assessment of nonmetastatic renal cell carcinoma: a clinically based model. Urology. 2001;58:141-145.
13. Cindolo L, de La Taille A, Messina G, et al. Preoperative clinical prognostic model for non-metastatic renal cell carcinoma. BJU Int. 2003;92:901-905.
14. Karakiewicz PI, Briganti A, Chun FKH, et al. Multi-institutional validation of a new renal cancer-specific survival nomogram. J CWM Oncol. 2007;25:1316-1322.
15. Patard JJ, Kim HL, Lam JS, et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol. 2004;22:3316-3322.
16. Cindolo L, Patard JJ, Chiodini P, et al. Comparison of predictive accuracy of 4 prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study. Cancer. 2005;104:1362-1371.
17. Justice AC, Covinsky KE, Berlin JA. Assessing the generalizability of prognostic information. Ann Intern Med. 1999;130:515-524.
18. Altman DG, Royston P. What do we mean by validating a prognostic model? Stat Med. 2000;19:453-473.
19. Hupertan V, Roupret M, Poisson JF, et al. Low predictive accuracy of the Kattan postoperative nomogram for renal cell carcinoma recurrence in a population of French patients. Cancer. 2006;107:2604-2608.
20. Kattan MW. Validating a prognostic model. Cancer. 2006;107:2523-2524.
21. Zisman A, Pantuck AJ, Dorey F, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol. 2001;19:1649-1657.
22. Guinan P, Sobin LH, Algaba F, et al. TNM staging of renal cell carcinoma: Workgroup No. 3. Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 1997;80:992-993.
23. Van Houwelingen HC. Validation, calibration, revision and combination of prognostic survival models. Stat Med. 2000;19:3401-3415.
24. Miceli R, Lusa L, Mariani L. Revising a prognostic index developed for classification purposes: an application to gastric cancer data. J Appl Stat. 2004;31:817-830.
25. Hemingway H. Prognosis research: why is Dr. Lydgate still waiting? J Clin Epidemiol. 2006;59:1229-1238.
26. Karakiewicz PI, Hutterer GC. Predicting cancer-control outcomes in patients with renal cell carcinoma. Curr Opin Urol. 2007;17:295-302.
27. Kunkle DA, Haas NB, Uzzo RG. Adjuvant therapy for high-risk renal cell carcinoma patients. Curr Urol Rep. 2007;8:19-30.